Literature DB >> 8143077

Utilization of an antibody specific for human dystrophin to follow myoblast transplantation in nude mice.

J Huard1, G Tremblay, S Verreault, C Labrecque, J P Tremblay.   

Abstract

Human myoblasts were transplanted in nude mice. The efficacy of these transplantations was analyzed using a monoclonal antibody (NCLDys3) specific for human dystrophin. This antibody did not reveal any dystrophin in nude mice that did not receive a human myoblast transplantation. However, about 30 days after a human myoblast transplantation, dystrophin-positive muscle fibers were observed. They were not abundant, and were present either in small clusters or isolated. This technique follows the fate of myoblast transplantation in animals that already have dystrophin, and distinguishes between new dystrophin-positive fibers due to the transplantation and the revertant fibers in mdx mice. Moreover, this technique does not require any labelling of the myoblasts before transplantation. It can also be used to detect dystrophin produced following the fusion of myoblasts transfected with the human dystrophin gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8143077     DOI: 10.1177/096368979300200204

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  9 in total

1.  Obestatin Increases the Regenerative Capacity of Human Myoblasts Transplanted Intramuscularly in an Immunodeficient Mouse Model.

Authors:  Icia Santos-Zas; Elisa Negroni; Kamel Mamchaoui; Carlos S Mosteiro; Rosalia Gallego; Gillian S Butler-Browne; Yolanda Pazos; Vincent Mouly; Jesus P Camiña
Journal:  Mol Ther       Date:  2017-07-24       Impact factor: 11.454

2.  Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

Authors:  Sébastien Goudenege; Yann Lamarre; Nicolas Dumont; Joël Rousseau; Jérôme Frenette; Daniel Skuk; Jacques P Tremblay
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

3.  Skeletal Muscle Regenerative Potential of Human MuStem Cells following Transplantation into Injured Mice Muscle.

Authors:  Judith Lorant; Charlotte Saury; Cindy Schleder; Florence Robriquet; Blandine Lieubeau; Elisa Négroni; Isabelle Leroux; Lucie Chabrand; Sabrina Viau; Candice Babarit; Mireille Ledevin; Laurence Dubreil; Antoine Hamel; Armelle Magot; Chantal Thorin; Laëtitia Guevel; Bruno Delorme; Yann Péréon; Gillian Butler-Browne; Vincent Mouly; Karl Rouger
Journal:  Mol Ther       Date:  2017-10-20       Impact factor: 11.454

4.  A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration.

Authors:  Michael V Khanjyan; Jonathan Yang; Refik Kayali; Thomas Caldwell; Carmen Bertoni
Journal:  Hum Mol Genet       Date:  2013-04-23       Impact factor: 6.150

5.  High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice.

Authors:  J Huard; S Verreault; R Roy; M Tremblay; J P Tremblay
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

6.  Dystrophin-positive muscle fibers following C2 myoblast transplantation into mdx nude mice.

Authors:  Y Hagiwara; Y Mizuno; M Takemitsu; T Matsuzaki; I Nonaka; E Ozawa
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

7.  Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation.

Authors:  Sébastien Goudenege; Carl Lebel; Nicolas B Huot; Christine Dufour; Isao Fujii; Jean Gekas; Joël Rousseau; Jacques P Tremblay
Journal:  Mol Ther       Date:  2012-09-18       Impact factor: 11.454

8.  Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane.

Authors:  Cosimo De Bari; Francesco Dell'Accio; Frank Vandenabeele; Joris R Vermeesch; Jean-Marc Raymackers; Frank P Luyten
Journal:  J Cell Biol       Date:  2003-03-10       Impact factor: 10.539

9.  Vascular Delivery of Allogeneic MuStem Cells in Dystrophic Dogs Requires Only Short-Term Immunosuppression to Avoid Host Immunity and Generate Clinical/Tissue Benefits.

Authors:  Judith Lorant; Thibaut Larcher; Nicolas Jaulin; Benoît Hedan; Aurélie Lardenois; Isabelle Leroux; Laurence Dubreil; Mireille Ledevin; Hélicia Goubin; Sophie Moullec; Jack-Yves Deschamps; Chantal Thorin; Catherine André; Oumeya Adjali; Karl Rouger
Journal:  Cell Transplant       Date:  2018-06-05       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.